Tumor suppression is a central theme in oncology, emphasizing the processes that inhibit cells from proliferating unchecked and progressing to cancer. The session on Tumor Suppression emphasizes the biology, clinical significance, and treatment implications of tumor-suppressing pathways.".
Tumor suppressor genes like TP53, RB1, and PTEN are important regulators of cell cycle progression, DNA repair, apoptosis, and senescence. Loss or inactivation of these genes through mutations, epigenetic changes, or deletions can result in cancer development and tumor growth as the cells escape from growth control mechanisms. It is important to know these pathways for discovery of biomarkers, prognosis of disease, and the design of targeted treatments.
The session discusses approaches to the restoration of tumor suppressor function or the exploitation of the vulnerabilities introduced by their loss, such as gene therapy, small-molecule modulators, and synthetic lethality strategies. Development in molecular profiling and personalized medicine allows clinicians to identify potential patients to be treated with therapies for tumor suppression pathways.
Participants will learn about the mechanisms, research progress, and clinical translation of tumor suppression. This session highlights how the activation of tumor-suppressing pathways can inform novel cancer therapies, enhance patient outcomes, and evolve the precision oncology field.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
